Table 1.
Baseline characteristics, clinical setting, causative organism, management, and clinical outcomes of the patients with endophthalmitis caused by gram-positive bacteria resistant to vancomycin.
| S.no | Age/sex | Clinical setting | Duration of symptoms (days) | Culture report | VA at presentation | Primary intervention | Second intervention | No. of IOAB | Follow-up duration (weeks) | Antimicrobial susceptibility Results | Final VA |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 45/M | Trauma | 3 | Bacillus species | LP | CTR + T&I (V + A) | A + D | 2 | 12 | S – C, CFC, GFC, A Int – MFC R—V, Cefa, OFC |
NLP |
| 2 | 70/F | Postoperative | 20 | Staphylococcus aureus | LP | PPV + T&I (V + A + D) | Cefa + D | 4 | 16 | S – Cefa, A, T Int - MFC R—V, C, CFC, OFC, GFC, |
LP |
| 3 | 3/M | Trauma | 3 | Staphylococcus aureus | LP | PPL + PPV + T&I (V + I + D) | Cefa + Da | 5 | 24 | S – C, Cefa, Int– CFC, MFC R—V, OFC, GFC, A |
CF |
| 4 | 54/F | Postoperative | 45 | Coagulase-negative Staphylococcus | CF | PPV + T&I (V + C + D) | A + Da | 5 | 56 | S - A R—V, C, Cefa, CFC, OFC, GFC, MFC, T |
20/200 |
| 5 | 57/M | Postoperative | 30 | Coagulase-negative Staphylococcus | HM | AC Tap + T&I (V + A + D) | Cefa + Da | 2 | 8 | S – C, GFC Int– MFC, Cefa R—V, CFC, OFC, A |
LP |
| 6 | 31/M | Trauma | 1 | Coagulase-negative Staphylococcus | LP | CTR + BB + PPL + PPV + IOFBR, T&I (V + A + D) | Cefa + Da | 2 | 90 | S – C, GFC, Int – MFC,Cefa R—V, CFC, OFC, A |
20/40 |
| 7 | 4/M | Trauma | 3 | Streptococcus species | LP | CTR + T&I (V + A + D) | Cefa+a | 3 | 12 | S – C, T Int– V, CFC R – Cefa, OFC, GFC, A, MFC |
CF |
| 8 | 5/F | Trauma | 5 | Streptococcus pneumoniae | LP | PPL + PPV + T&I (V + A + D) | Cefa + Da | 4 | 20 | S – C, Cefa, CFC, GFC, MFC, T R—V, OFC, A |
LP |
| 9 | 56/F | Postoperative | 6 | Staphylococcus aureus | HM | T&I (V + A + D) | L + D | 2 | 78 | S – A, L Int– C, MFC R—V, Cefa, CFC, OFC, GFC |
20/40 |
| 10 | 36/M | Trauma | 5 | Coagulase-negative Staphylococcus | HM | PPL + PPV + IOFBR + T&I (V + I + D) | Cefa + D | 4 | 36 | S – C, Cefa, Int - CFC R—V, A, OFC, GFC |
20/200 |
| 11 | 67/M | Postoperative | 2 | Staphylococcus aureus | HM | T&I (V + I + D) | L + D | 5 | 36 | S – CFC, OFC, GFC, MFC, L R—V, C, Cefa, A |
20/60 |
| 12 | 51/F | Postoperative | 3 | Coagulase-negative Staphylococcus | CF | T&I (V + I + Vor + AmpB) | Cefa + D | 3 | 24 | S – C, Cefa, L Int – CFC, A, MFC R—V, OFC, GFC, |
20/30 |
| 13 | 66/F | Postoperative | 10 | Coagulase-negative Staphylococcus | CF | T&I (V + I + D) | L + D | 2 | 6 | S – A, MFC, L Int – Cefa, CFC R—V, C, OFC, GFC |
LP |
| 14 | 68/F | Postoperative | 5 | Staphylococcus aureus | HM | T&I (V + I + D) | L + Db | 5 | 12 | S - L R—V, C, CFC, GFC, OFC, MFC, Cefa, A |
20/125 |
Abbreviations: A, amikacin; AC, anterior chamber; AmpB, amphotericin-B; BB, belt buckle; C, ceftazidime; Cefa, cefazoline; CF-counting fingers; CFC, ciprofloxacin; CTR, corneal tear repair; D, dexamethasone; F, female; G, gatifloxacin; HM, hand motions; I, imipenum; IOFBR, intraocular foreign body removal; Int, intermediate; L, linezolid; LP, light perception; M, male; MFC, moxifloxacin; NLP, no light perception; OFC, ofloxacin; PPL, pars plana lensectomy; PPV, pars plana vitrectomy; T, tazobactum; T&I, tap and inject; V, vancomycin; VA, visual acuity; Vor, voriconazole.
Pars Plana Vitrectomy was performed on subsequent follow-up.
Penetrating keratoplaty was performed at subsequent follow-up.